Aspire Biopharma Holdings (ASBP) Non-Current Assets (2022 - 2024)

Aspire Biopharma Holdings (ASBP) has 3 years of Non-Current Assets data on file, last reported at $6.5 million in Q2 2024.

• On a quarterly basis, Non-Current Assets fell 67.41% year-over-year to $6.5 million in Q2 2024; TTM through Jun 2025 was $6.5 million, a 90.14% decrease from a year earlier, with the FY2023 full-year figure at $19.9 million, down 93.35% from the prior year.
• Non-Current Assets for Q2 2024 stood at $6.5 million, down from $20.1 million in the prior quarter.
• Over the last five years, Non-Current Assets for ASBP reached as high as $302.2 million in Q1 2023 and fell as low as $6.5 million in Q2 2024.
• Historically, Non-Current Assets has averaged $157.5 million across 3 years, with a median of $157.7 million in 2022.
• On a YoY basis, Non-Current Assets climbed as much as 2.36% in 2023 and fell as far as 93.38% in 2023.
• Year by year, Non-Current Assets stood at $299.1 million in 2022, then slumped by 93.35% to $19.9 million in 2023, then slumped by 67.21% to $6.5 million in 2024.
• Per Business Quant data, the three most recent Non-Current Assets figures were $6.5 million in Q2 2024, $20.1 million in Q1 2024, and $19.9 million in Q4 2023.